Publication | Closed Access
Peculiar Acral Erythema Secondary to High-Dose Chemotherapy for Acute Myelogenous Leukemia
106
Citations
9
References
1982
Year
Mixed-phenotype Acute LeukemiaImmunodeficienciesPathologyYoung J. RaynaudDermatologyAcute Myelogenous LeukemiaInflammatory ArthritisHematological MalignancyOncologySurgical PathologyClinical EpidemiologyRadiation OncologyLymphoid NeoplasiaAutoimmune DiseaseClinical DermatologyHigh-dose ChemotherapyHarvey H. RaynaudDermatopathologyMolecular Diagnostic TechniquesAntibioticsMalignant Blood DisorderMedicine
Brief Reports1 July 1982Peculiar Acral Erythema Secondary to High-Dose Chemotherapy for Acute Myelogenous LeukemiaWALTER H. C. BURGDORF, M.D., WILLIAM A. GILMORE, M.D., RALPH G. GANICK, M.D.WALTER H. C. BURGDORF, M.D., WILLIAM A. GILMORE, M.D., RALPH G. GANICK, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-1-61 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCutaneous changes limited to the hands have been described in patients receiving cancer chemotherapy with regimens involving bleomycin. We describe a patient with a peculiar acral erythema treated with high-dose chemotherapy not incorporating bleomycin.A 50-year-old woman developed dysarthria, expressive aphasia, and fever while on vacation in New England. When examined in the local hospital emergency room, she had a leukocyte count of 18 000/mm3 with numerous immature and blast myelocytes. Bone marrow examination confirmed the diagnosis of acute myelogenous leukemia. Computed tomography showed a left posterior temporal lobe density consistent with a leukemic infiltrate or hemorrhage.The patient was...References1. VAUGHAN W, KARP J, and BURKE P. Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer. 1980;45:859-65. CrossrefMedlineGoogle Scholar2. TEUTSCH C, LIPTON A, and HARVEY H. Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep. 1977;61:925-6. MedlineGoogle Scholar3. ROTHBERG H. Raynaud's phenomenon after vinblastine-bleomycin chemotherapy. Cancer Treat Rep. 1978;62:569-70. MedlineGoogle Scholar4. SOBLE A. Chronic bleomycin-associated Raynaud's phenomenon [Letter]. Cancer Treat Rep. 1978;62:570. MedlineGoogle Scholar5. CHERNICOFF D, BUKOWSKI R, and YOUNG J. Raynaud's phenomenon after bleomycin treatment [Letter]. Cancer Treat Rep. 1978;62:570-1. MedlineGoogle Scholar6. SUNDSTRUP B. Raynaud's phenomenon after bleomycin treatment. Med J Aust. 1978;2:266. CrossrefMedlineGoogle Scholar7. VOGELZANG N, BOSL G, JOHNSON K, and KENNEDY B. Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288-92. LinkGoogle Scholar8. KUKLA L, BURROWS D, BRESSLER L, and MCGUIRE W. Bleomycin-induced Raynaud's phenomenon. Arch Dermatol. 1981; 117:604. CrossrefMedlineGoogle Scholar9. COHEN I, MOSHER M, O'KEEFE E, KLAUS S, and DE CONTI R. Cutaneous toxicity of bleomycin therapy. Arch Dermatol. 1973; 107:553-5. CrossrefMedlineGoogle Scholar10. VON EYBEN F, BRUZE M, EKSBORG S, MATTSSON W, and JONSSON K. Toxic epidermal injury following intraarterial adriamycin treatment. Cancer. 1981;48:1535-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: WALTER H. C. BURGDORF, M.D.; WILLIAM A. GILMORE, M.D.; RALPH G. GANICK, M.D.Affiliations: Department of Dermatology University of Oklahoma Health Sciences Center Oklahoma City Clinic Oklahoma City, Oklahoma PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDesign of amino acid- and carbohydrate-based anticancer drugs to inhibit polymerase ηCutaneous Adverse Drug ReactionsRecognition and Management of Toxic Erythema of Chemotherapy for the Inpatient DermatologistCytarabine ears – A side effect of cytarabine therapyCommon Cutaneous Side Effects of Anti-cancer AgentsAdverse Cutaneous Reactions to Chemotherapeutic AgentsCutaneous Adverse Drug ReactionsThe interface reaction pattern in the skin: an integrated review of clinical and pathological featuresKutane ArzneimittelreaktionenKutane ArzneimittelreaktionenSemelles orthopédiques et prévention du syndrome mains-pieds lié aux traitements anticancéreuxMultikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management"Red Hand Syndrome" Due to Cytarabine in a Case of Mantle Cell LymphomaAutologous GVHD?Risk Factors for Cytarabine-Induced Cutaneous Toxicity in Patients with Haematological MalignanciesAntimetabolite ReactionsThe History of Supportive OncodermatologyConnect the dotsTECToxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplantIntertriginöse ErythrodysästhesieBilateral Ear Swelling and Erythema After Chemotherapy: A Case of Ara-C EarsBullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*Cutaneous adverse reactions to drugsChemotherapy-induced iatrogenic injury of skin: New drugs and new conceptsThe emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesDia-KlinikThe hand-foot-syndrome associated with medical tumor therapy - classification and managementRandomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesiaCutaneous Adverse Drug ReactionsToxic erythema of chemotherapy: A useful clinical termRisk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysisDrug Eruption Induced by Imatinib Mesylate (Glivec)Palmar–plantar erythrodysesthesia due to docetaxel–capecitabine therapy is treated with vitamin E without dose reductionHand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case SeriesVascular Toxicity of Antineoplastic AgentsPalmoplantare Erythrodysästhesie nach intravenöser Therapie mit DocetaxelThe juvenile variant of papular-purpuric gloves and socks syndrome and its association with viral infectionsChemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome: Etiology and Emerging TherapiesManagement of hand-foot syndrome in patients treated with capecitabine (Xeloda®)Palmar-plantar erythrodysesthesiaRecurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemiaCutaneous toxicities of cancer therapyIncidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution ExperienceChemotherapy-induced bullous acral erythema in a subject with B-cell lymphomaChemotherapy-induced acral erythema: report of a case and immunohistochemical findingsPersistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristineSubungual abscess: a new ungual side-effect related to docetaxel therapyBullous acral erythema and concomitant pigmentation on the face and occluded skinAcral Erythema in Children Receiving High-Dose MethotrexateMucocutaneous reactions to chemotherapyHigh Incidence of Chemotherapy-Induced Acral Erythema in Female Patients with non-Hodgkin's Lymphoma Treated with the Vacop-B RegimenAcral erythema and intrahepatic 5-fluorouracil infusionA Case of Acral Erythema Induced by Methotrexate.Hydroxyurea-induced dermatomyositis-like eruptionThree Cases of Chemotherapy-induced Acral ErythemaSkin ToxicityEtoposide-related acral erythemaThe cutaneous histopathology of chemotherapeutic reactionsNew Histopathologic Findings in Drug EruptionsNecrotizing eccrine squamous syringometaplasia presenting as acral erythemaPainful, Red Hands.Skin problems in advanced and terminal cancer patientsChemotherapy-induced acral erythemaPapular-purpuric "gloves and socks" syndromeErythema and swelling of ears after treatment with cytarabine for leukemiaSkin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapyA Variant of the Chemotherapy-Associated Erythrodysesthesia Syndrome Related to High-Dose CyclophosphamideAcral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemiaAcral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusionsDermatologic Effects of CancerPainful red hands: a side-effect of leukaemia therapyHypersensitivity reactions from antineoplastic agentsChemotherapy-Associated Palmar-Plantar Erythrodysesthesia SyndromeJOACOB J. LOKICH, M.D., CHERYL MOORE, R.N.Acral Erythema and HydroxyureaFRANCES SANDLER SILVER, M.D., LUIS R. ESPINOZA, M.D., ROBERT C. HARTMANN, M.D.Cancer Chemotherapy and Acral ErythemaHENRY SCHNEIDERMAN, M.D., NICHOLAS ROBERT, M.D.Cancer Chemotherapy and Acral ErythemaCATHERINE CORDONNIER, M.D., JEAN CLAUDE ROUJEAU, M.D., JEAN PAUL VERNANT, M.D., SOPHIE MATHERON, M.D., GERARD GANEM, M.D.Arzneireaktionen 1 July 1982Volume 97, Issue 1Page: 61-62KeywordsAcute myeloid leukemiaBone marrowCancer chemotherapyComputed axial tomographyEmergency departmentErythemaFeversHemorrhageHigh-dose chemotherapyTemporal lobe ePublished: 1 December 2008 Issue Published: 1 July 1982 PDF downloadLoading ...
| Year | Citations | |
|---|---|---|
Page 1
Page 1